Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Johnson & johnson save search
Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine Candidate
Published: 2022-06-16 (Crawled : 10:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
covid-19 vaccine program update phase 3
Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Published: 2022-06-03 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.68%
H: 0.0%
C: 0.0%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
imbruvica risk disease results order phase 3
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
hypertension positive phase 3
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.68%
C: 0.27%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: -20.04%
H: 28.04%
C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
Published: 2022-04-20 (Crawled : 06:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
vaccine trial phase 3 order
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial
Published: 2022-02-28 (Crawled : 07:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
covid-19 phase 2 trial covid report positive phase 2 results results vaccine phase 3
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
Published: 2021-12-15 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.76%
H: 2.5%
C: 2.5%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: 0.0%
covid-19 trial covid positive vaccine phase 3
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
Published: 2021-12-11 (Crawled : 16:20) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
| Email alert
Add to watchlist
imbruvica treatment leukemia disease phase 3
Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base
Published: 2021-12-06 (Crawled : 07:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.49%
H: 0.0%
C: 0.0%
trial vaccine phase 3
Latest Phase 3 Data for First-in-Class TREMFYA® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis
Published: 2021-12-03 (Crawled : 13:30) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
test phase 3
Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149
Published: 2021-11-15 (Crawled : 09:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: 0.0%
ADXN | $19.28 -10.32% 13K
|
Health Technology
|
| O: 2.85%
H: 1.14%
C: 1.14%
phase 1 phase 2 xin phase 3
New Phase 3 First-in-Class TREMFYA® (guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)
Published: 2021-11-01 (Crawled : 14:15) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
phase 3
New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
Published: 2021-11-01 (Crawled : 12:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
disease phase 3
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: 4.89%
H: 1.6%
C: -1.84%
vaccine phase 3 approval sars-cov-2
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
Published: 2021-09-29 (Crawled : 13:15) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.12%
H: 1.02%
C: 0.63%
respiratory vaccine phase 3 trial order
Arrowhead Earns $10 Million Phase 1 Milestone Payment
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: -6.56%
phase 1 phase 2 phase 3 milestone
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Published: 2021-09-28 (Crawled : 07:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.5%
C: -0.18%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
phase 1 positive results vaccine phase 2 phase 3
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
Published: 2021-09-27 (Crawled : 14:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.44%
H: 0.22%
C: -0.51%
blood risk positive phase 3
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Published: 2021-09-21 (Crawled : 11:00) - prnewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.71%
H: 0.83%
C: -0.05%
covid vaccine phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.